{"id":863484,"date":"2025-06-25T06:06:24","date_gmt":"2025-06-25T10:06:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/"},"modified":"2025-06-25T06:06:24","modified_gmt":"2025-06-25T10:06:24","slug":"first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/","title":{"rendered":"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong><br \/>\n            <em>The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong><br \/>\n            <em>CLARITY is a randomized clinical trial designed to demonstrate Nociscan\u2019s ability to improve surgical outcomes for chronic low back pain <\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong><br \/>\n            <em>Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong><br \/>\n            <em>Company reaffirms internal interim results of CLARITY expected in Q2 2026 <\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p>BROOMFIELD, Colo., June  25, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HDtEWk54r0OhSPTmZxzQhbihFXVAOlDizQAhsLAWmZdn2-lk-VUNETADvgCvTbAVW937XGiLG2tCvT6l4gH_Ow==\" rel=\"nofollow\" target=\"_blank\">Aclarion, Inc<\/a>., <strong>(\u201cAclarion\u201d or the \u201cCompany\u201d) (Nasdaq: ACON, ACONW), <\/strong>a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the first patient enrollment in the CLARITY (<strong>C<\/strong>hronic\u00a0<strong>L<\/strong>ow b<strong>A<\/strong>ck pain\u00a0<strong>R<\/strong>andomized\u00a0<strong>I<\/strong>ndependent\u00a0<strong>T<\/strong>rial stud<strong>Y) <\/strong>trial evaluating Nociscan\u2019s clinical and economic value in spine surgery. The first patient was enrolled at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jy7d2HXHTb7E0LCHvjAOQNLpsrVak3ysKve7MEj1rLhSk7oTy5l-Uik_asg6cqZgXtcWfnlj3a36isxhzNvwDKu3wQn3o13eKnTWsZMGJNE=\" rel=\"nofollow\" target=\"_blank\">Texas Back Institute<\/a>.<\/p>\n<p>\u201cTexas Back Institute has a long history of advancing spine care through clinical trial research,\u201d said Alexander Satin, MD, board-certified orthopedic spine surgeon and principal investigator for the CLARITY trial. \u201cWe have followed the advancements from Aclarion and their Nociscan platform.\u00a0The CLARITY trial will allow us to observe patient-specific critical pain biomarker data and the relationship with surgical outcomes. Our physicians and research leaders have extensive experience treating patients with chronic low back pain and we are pleased to participate in this important trial, including enrollment of the first patient.\u201d<\/p>\n<p>The CLARITY trial is a prospective, randomized multi-center study evaluating patients who are scheduled to undergo surgical treatment of 1- or 2- level discogenic low back pain. The study will enroll 300 patients at multiple high-volume sites across the US and all patients will receive a Nociscan prior to surgery. The study will be randomized at a 1:1 ratio of surgeons blinded-to-Nociscan and unblinded-to-Nociscan to guide the surgical treatment (Fusion \/ TDR). The primary endpoint is change in back pain as measured on a 100mm VAS Back at 12 months compared to baseline, with several secondary endpoints collected. The principal investigator for the trial is Dr. Nicholas Theodore of Johns Hopkins Medicine. Other sites that have been activated include Northwestern Medicine, Advocate Aurora Research Institute, Keck Medicine at USC and UHealth &#8211; University of Miami Health System and University of Miami Miller School of Medicine.<\/p>\n<p>Chronic low back pain is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion\u2019s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain and has the potential to drive better surgical outcomes.<\/p>\n<p>For more information about CLARITY, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P8jXqsVkdtqkGgdrVr5dFmjW7_CBPyU2NyzahxKmaSSX1-oyErix2gFlxx-V0ZtWhrDHCj-oH2dJC4BmXg13p9p-qzJSYlBKfaOnXbZ6rfDRetODAanAgCgUd0B46AN5SPC9pG7oj68xqm9CrX7mJu_Kz-nJM8tTploOJlHdEaGUWVCwwBQXA8oyV8OIarJzPYNYLaObj9bwhnB_nKuOjyimY1g_S81TJ52Fj98Zprs6cuaYjrWcx8rkflEwaWI-wiHhiPyNPZ0sfSdWPa7WakVJGyAgDAkY12TKMwyzhkeNLJsudP7mw9NLrBvp1tGs2QQ6tYREIjbvqHbMTn4oY6N9yUjRN_DXydS5sUxrDQNu3rjSGULMNLOAlavuXzeSVr_33cmhubxk7lnqJcrVVvAOt1p61uG6_ozu90-gu65wXcqsCnmHIH0349CWQvp5_Bp1w6eE1WrKC5WcLgO0tAd5awyKFP3k1MX3N3NThlOVIYflvoV5VhVluPnYPBgYumNGabyCqP30xr80ySYlJFGR7zFZgr0ov9TIwznaUUUuzJobbhc3BwzWwP49JBz3Rw8TIXGoqptTosS504tsZgKyyb0GAsExreGvVJCC_-L0YOjkX61_cz-QAQNWGw_S6qpts8NcXJuOweByD04OrFUOiii3p1qV0BXrVPgx1naBJHgh_N4-x3o4CTWysAU6yjsOdKclkSTzA0E3T7uB2rM6ZdtW1QAbDKgJd6ulMdTHel1p7RmWKbMRgZRNBxX-YgLe41WhzmxtgzTqmwP1t-z3yPxCdMogMJuHEuCyIru0HO0WEjGJ13tpWdIjlfL9wGz5yhVgANr0OMM11U93eryp8RBrftvHo0tWsrBaVO2321BzK5YyIgs7KxN9Nnhplcg1ep-hTOOI6rffnoNAAvYCh7h88gn2Qa2nJCSCpMgzeMV2Rv1K0Qon_HKErsgeYjtdz2IYEf-YswwFdOGobR0Um7G77Z76QdttapHpxtSY1kpbrkgNh8fI5Z5VdDktn9n66dVuhG3oebzartxacpeD9RSWkDAvnQRrbFu9UsYvg1nYp3M4avuYByFVTvgJcHzfZe1cPwJmw8DJlhl_HQ==\" rel=\"nofollow\" target=\"_blank\"><strong><u>CLARITY Trial <\/u><\/strong><\/a><\/p>\n<p>To find a Nociscan center, view our site map <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y2sxsMiQjXsfOC-aEXpEQBS3wxHjZU9X7LqF-p9kGNOHvuvu9iPqoA3YiZ3yecrEvUwKn9NkuuafsXzip_qJQh_gjPhlGE4YIDi8JLdHKTOw9f8ejl5puZIT1y2Pt156Rs5v9xNvvR1KlAzPFm_j0Ibrfs9GZ1K6V3SrrHIC-5TSkEbSUt13C_bxrKqZ4Tf6QpxihCOFkrrMlMWjN77-WJId86wXP-WshUDqL-VTgxNMcWC-5b28PrGWyTbDL-ZnHLpQhQAqxNpDfXAEHAbICTezOQ7PonYuoPMnGv6fbTwaBOl2toI2Naupvz5gtMD4UeaAhWeVM9iH4wCuhlg9AEGdyJ5i6HR8dF4CVr0Rrett4CRh8914Aj8Mdo88yo8akPscZIOAnll5DNVKlAxgK8b_Pj3mQjetRvzJIsDIzGyGJwYI2XDHxBWfVvRaBp7K3bEOcWjEgM63Cw-WyKUzqcAiRV742QAbf_ltdtCQx7NPz7LqKTuSVQ1AvQ3X-inGh4b9sulCaI-KTzTfZpTuQgdAPEm7h23QQJHpgy7PO3c7XP8zirfR_X70RXuIfS8GW6gorxgZYi03x6UxXVzZgfifV7vhIXXtimI7qZLp7wwFO34cNKNjJ3pIGdJXfuB4oNwDQyoRO23bLF9v_PZ_k5AcAz_NMAI0i6-OopUATdXTci73FJW3I3_IznWogLB783ReVuQU_BNIxHygE1aS4QtpWDxodj8DiDLc7cdsxDrNiEqfUolZ-Vl0AqpszvZgcGrD_WyRECUigMpmdohokDWY30c8IyPRmbxiAS7feoWgDfucMfRQ1_H637dPt5TWkRvsxyYFvhZBRvpJ1UO4UIRqCcqFw4CUmYcHLfIBWr7RIcMdFEWlOq7njOIUStXZ_CK5Q8CK2Zz3thxAbRT8U64qNWj0wmJ9-KmZOZzE2FCz8UwVmy2Q2gMQGEDCLbw-ubIql6Cfy0CJC19xby55jtJ1t6RuYEWa3LJfPIXzfyEsDonTL8KbZHVFLza5iEO_sqCoMod3PphHoD1rgD_Fp0_bOk_nShbuOiKtRU1Uo-8=\" rel=\"nofollow\" target=\"_blank\"><u>here<\/u><\/a>.<\/p>\n<p>For more information on Nociscan, please email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kn1_yYmMJCH9EnFKf98z2UQ5HTQ4X2YqqQtSJ-HSYvKG7efUHMvbAWhtEMspkRQwUJDWOO9xjuC5EN6UQF6FgAWCW8Ct1n7o5YpZxvd0OA6oQOiU5ZOuKOIoa5zXCIu9UBI2tCbm1baTCRhKfCRqcjxf850ZY_8Q06B9GvgSEYBUf9mR2Zk-dgBcNO9PRCRCWqwD_2KhJgaqkdwquGxAfWLqJ9tNnEejNkhROLpzc4gnWhskZs0GkAQu3SacAJWoIBVYrGpHeApGQg1KXMdQPTM_m_qo-cUWrzdhm8vmoXGPYDXOCnAKnpApDBWJBHl-4x4P42oDI3jksyj7WO6JNwLb-_LTKBnQVEN40lFMWVWR4Pj5w0QCW5W0tJOV0PWvcJYA2z3W2tokQ2HZYya35UrNWMio5KMx8pBeLALSWTFOKh2YlDVyZX6kpOTqxuoxhk7HUyExywezrptO4KdPKIuJ9993haPczOSd8zoNC55ZyUvV8Q4YBjqjMGyD-iin7u-YqYVtJDQ5tc8eDKpHrT3QOiYRDwOmYaeKUajCj00F3VbBuTwxbxOEJ5d3bhDt4WqXQT9cvp_k91H6snsq79ZwQxoxqkMvewi0cZbozDne79rJvT4aleWg3k1yRWV7hxnm_asnT5Z1hoLewzmRct9m6qPh9cBRmvtY3o9QrrCq7eAWMi5pd_yiVVndxg_D7g2cMd77jAOSriFF0o1M1IYUPnxl292MfdXc_HfJqELPnAnMBUFThHXCwMq2k4VPTjNlHbzU7bCSJpawPSecJDGYZaaOBFF169-2PmOsM-_ucqDLLHVGQieFLho0RSUeI3xkSA7zKk9oR4gGabfs3W9nrEKL6rWQhMqGvDEx84MLnH2tFaf-QGVn8DBRy1GmVMJnUiC8HF3p-X1ZVXiud0-hVKXQ35HTiz0ALmitQcYWMHWGh2FjsvyHcg91echCXWd1maFMcb67rL6MH-U3jXd0U3nz7ysfTbtxykgvhplBi0yjAxx80XkEcXlE0pZxeTrlIBpIVnE8eQ_bTU7ZyvmGdRZHGGxbIIkMJG-hI3LHV45V3o5R4nfbZ8_Epslp_PrY_TShU5Pj7KCk2a1avQ==\" rel=\"nofollow\" target=\"_blank\"><u>info@aclarion.com <\/u><\/a><\/p>\n<p>All organizations cited and\/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein.<\/p>\n<p>\n        <strong>About Aclarion, Inc. <\/strong>\n      <\/p>\n<p>Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (\u201cMRS\u201d), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient\u2019s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=grSg0d8quR7uR717t-Ast84eFeTlpjng5nUOwEkI0SK8LysNrf898CII32wgTGLRKhnFIaw5xsg-IjM1Uvo1rr9x3_8cHPuTtpWTT7JE-SwR-FHNwTlJzKWZcF8pttBxAO18xT5rU5PFNkSBFlGm-lQRuct-AlQNz0n3amTJHtI3UU_cEqtZ4Xd3iMEtMuIAeRw0WCwxIC0ikc_tQVSz3zGOo5CPnWvsI9ncbTUIIyLhda1fQE4ryzT9BvOS2FQoAGg31Kr19p6a0mXfjw2KjuLQ6eBpxCGoYJB31nT_Ui9PmjhTwHsgT5hv97mXQmRPjO8j0wI9lmL4_vJ-VKg0FlX79fUcvHHROsG0dlIkG74vX28INgznmhsvh0OAoXEKjXObQOlvkqZkH7fgeAxI3ModDQXL2jV_5UeEs0DtASRYpsQSqy7f1NwSNHHms3Rvn2_BuiY5MOf4tdWhodoNRUEdOGPgNF7oqwSKc1U-q7MDkTbmUdipiF_qsutyXCataWa_Kc5JGy2eK_whk76cUjy5Ya9L6F9KxLP5TJY04hiDbsWhPERAkYixRkJrzci9HbF-rxPv3oYiRpcNLMmrpN2wGouYsSBgRxSSU6CWxhHL-YXTrob1QNyogNAwratMek1tOREBU9pPXGYyg39G9X4LJx9GUhGpCHMsU-cMv8CkgPj6eZIZpC4HBWuq7ZU2ylZPyYk41aF9jFs8FhZNjlC7H9yQfw7Vr9ccaVtfVqSJqRfJhllJLg4GohEJnM-DQxR5GtQDuRfDRm2PFlnsWEOtlumY5byA62knMa7kctb7EihAKKdDFhaZI3kCkiRGuzi7OVG5rTdCpef-XsCaQ2EIs9dIkaBgPoRhCnj2JMIusIy5uqaQEw8wWVDMtuhV76fUzHQasERwkJtXdaoFgtTD4Tlok18jf72ekFyBSAy9avTYRK1f09lEY18j96y5QwTl1jt7RJM1dAa2tDCeA-IHb60xhgi9HUJBKOO-l9gqioUEdUWjnYhNt5fP9SV-Oa1H8_xvLC4CmHkbiJtRFv4BMPyimqhSiN10o8bfxnhqy2G-6M8y4nxyQe6VfWp3eNk7OlimlF1SmjJ8DsyD_g==\" rel=\"nofollow\" target=\"_blank\"><u>www.aclarion.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company\u2019s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as \u201canticipates,\u201d \u201cbelieves\u201d and \u201cexpects\u201d or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company\u2019s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Investor Contacts: <\/strong>\n      <\/p>\n<p>Kirin M. Smith <br \/>PCG Advisory, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z2cf9ZK48GX2lSKa_uNlerS8XgTpDfTtIFFbDWsxR5DvXO92_evnmpzmXA2t6X_8wWoMbMi01FcrrySrShSuSTGlPksqd9a-OYpWXxWhj3K2F2wvlLHXbn5XZ-492wuHpZKHp3tjkPmJsM9Nvozd9TDEfgJGmAIsWsCgSI96SnmsAVNVcAn9phE_GiQohAb28C49BkNrsOSroqeo8p23qAwKRZCtS9odgoh8yHPjex9LTRu4b4o3Z6_yzG3GcFyS6JjpGx-ncyuS5X-vA3iiCBKln4Rio6V2PRrYfVvyVe82qPqfZTLKCN41eWJJaI62a565UnxBZcnFCEVEyFMr1gIHBEA4yTUP3ij8og-46e7fNyb153xMj40QYpBW8bbZSPZymbQUlTmzRfvBLo20sX0uhPBHEtzH3G6KtlD5tnpGcltxHOALltwZUEzCQ6mUT5FGnOzXXh_o0m1IHJmnpEDebMQfA_UjbUSBYTNDyQPKk02HCxXcdBSEXa84PX4xe-U3IPLuNKp_OBNHVfWNq1U2wotMz534lGB4ilBy4-JJJVzglqd_QIAXpdpce7Dr1GejhJ4nND7zKF3jF6sa6iSYsiZWR98EXpHqZr7q-soRxT9sm3Unj5Sg_WUKQCDzusvt9SzB7TF6WL4ckvfXEbkr0hTioGuoTfHhK0QuMW8NWC8KD5G0FWAXBIsDe1Z2ersJdc2TsbsCG_T_7IZNOOPsQtN6Dsz9ItkE_GB9FGMifEY82gIRn6aqutRutUiYkh-hDdL8q_TfF9ihFU0CS2A5D9nPNLPbphNVX1V6DQJSqfkhErPWrPIDPeFQ_A5UU2nfg7vJaD0hPMaqc8bXCVLW6eh0P5G6KR99JJ-WC1Puq88oLInsgrEyztZFgQ1Gk9Sce1QgUsquiqI9DVTFOhj2v3fg8ldht-MD3pOee88dh8V7dOEVj4t63quUIFSkXbu03dtotJYmiKcatVEI_fNsAZGluuswVWU1YvdXmu54r0qsqteWkjEHeyrgVR3p6huL2UVij463tz9nW0VweeoZ8IfA4LwM-hKenEfwGjrZajcvl0nXMauEFHG_lXm4lhDtUKaA_lBxGZB9dcQ848WHDzf9CXVtrTHGYVvlgcs=\" rel=\"nofollow\" target=\"_blank\"><u>ksmith@pcgadvisory.com <\/u><\/a><\/p>\n<p>\n        <strong>Media Contacts: <\/strong>\n      <\/p>\n<p>Jennie Kim <br \/>SPRIG Consulting <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aSYrhO7r2jyizMoLfe7JSY7dU3H3CMolIkjDhjFgHlzlo4pzc0XxficwoXQTcfmMaEMitE2KPlDD1stJbrZwDxKHBPPWypY8tk_f5YGe22ulv9qRFsUUr1Et9MpXHph6\" rel=\"nofollow\" target=\"_blank\">jennie@sprigconsulting.com <\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTVhNDQ2NGMtNDYwNy00MGZkLTk2ZWUtMTViNGEyZjZiMmM4LTUwMDEzMjI4Ni0yMDI1LTA2LTI1LWVu\/tiny\/Aclarion-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan\u2019s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY expected in Q2 2026 BROOMFIELD, Colo., June 25, 2025 (GLOBE NEWSWIRE) &#8212; Aclarion, Inc., (\u201cAclarion\u201d or the \u201cCompany\u201d) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-863484","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan\u2019s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY expected in Q2 2026 BROOMFIELD, Colo., June 25, 2025 (GLOBE NEWSWIRE) &#8212; Aclarion, Inc., (\u201cAclarion\u201d or the \u201cCompany\u201d) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back &hellip; Continue reading &quot;First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-25T10:06:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial\",\"datePublished\":\"2025-06-25T10:06:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/\"},\"wordCount\":897,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/\",\"name\":\"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==\",\"datePublished\":\"2025-06-25T10:06:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/","og_locale":"en_US","og_type":"article","og_title":"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial - Market Newsdesk","og_description":"The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan\u2019s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY expected in Q2 2026 BROOMFIELD, Colo., June 25, 2025 (GLOBE NEWSWIRE) &#8212; Aclarion, Inc., (\u201cAclarion\u201d or the \u201cCompany\u201d) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back &hellip; Continue reading \"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-25T10:06:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial","datePublished":"2025-06-25T10:06:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/"},"wordCount":897,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/","name":"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==","datePublished":"2025-06-25T10:06:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4NDE5MSM3MDE3MzYxIzUwMDEzMjI4Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/first-patient-enrolled-in-aclarions-groundbreaking-clarity-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"First Patient Enrolled in Aclarion\u2019s Groundbreaking CLARITY Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/863484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=863484"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/863484\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=863484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=863484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=863484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}